ArticleActa diabetologica2026
Angiotensin (1-7) exaggerates albuminuria and nephrin gene expression but does not modulate renal function-specific microRNAs expressions in kidneys of db/db mice.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study investigated the effects of angiotensin (1-7) on diabetes-induced renal injury and renal miRNA levels in obese type 2 diabetic db/db mice.
methodsTreatment with angiotensin (1-7) (500 μg/kg; i.p.) was started when the mice were 12 weeks old and given daily for four weeks. Renal function was assessed by measuring creatinine clearance and albumin excretion rate. The effect of diabetes and/or angiotensin (1-7) treatment on renal miR-29a-3p, miR-29a-5p, miR-155-5p, and miR-30 mRNA expression was studied using real-time PCR. Nephrin and podocin mRNA and protein expressions were studied using real-time PCR and Western blotting.
resultsAt 16 weeks, diabetes caused a significant increase in albumin excretion rate, which was further increased with angiotensin (1-7) treatment. Diabetes and/or angiotensin (1-7) did not affect creatinine clearance. Real-time PCR showed no significant changes in expressions of miR-29a-3p, miR-29a-5p, miR-155-5p, or miR-30 in untreated or angiotensin (1-7)-treated control or db/db mice. There was no change in podocin mRNA or protein expression; however, nephrin mRNA expression was increased in angiotensin (1-7)-treated db/db mice. Nephrin protein expression was increased in kidney homogenates of db/db mice but was unaltered in renal membrane fractions. Treatment with angiotensin (1-7) did not affect nephrin or podocin protein expressions in homogenates or membrane fractions.
conclusionsThe marked albuminuria observed at 16 weeks in db/db mice was independent of the expression of the studied miRNAs or nephrin and podocin expression. Angiotensin (1-7) was not protective as it further exacerbated albuminuria despite having no impact on nephrin and podocin renal protein expression.
Indexed as
Identifiers
42171710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.